The approval covers all 30 European Economic Area countries, following a similar regulatory green light in Canada earlier this year. Developed as a serotype E botulinum neurotoxin, Boey functions by targeting SNAP-25, with clinical trials demonstrating visible effects as early as eight hours post-injection. The results typically diminish within two to three weeks, providing a distinct profile compared to conventional products that often last several months.

According to Darin Messina, senior vice president of aesthetics research and development at AbbVie, the move aligns with shifting consumer demands. Internal company research suggests that roughly 79% of potential patients desire a way to preview aesthetic outcomes before committing to longer-term results. By offering a transient effect, the company aims to lower the barrier to entry for individuals curious about injectables but wary of lasting physical changes. Allergan Aesthetics is currently preparing for a commercial rollout across Europe, with plans to support practitioners through specialized training on the product's application.